Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) EBT (2016 - 2025)

Anaptysbio (ANAB) has disclosed EBT for 10 consecutive years, with $49.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 328.06% year-over-year to $49.7 million, compared with a TTM value of -$13.1 million through Dec 2025, up 91.0%, and an annual FY2025 reading of -$13.1 million, up 91.0% over the prior year.
  • EBT was $49.7 million for Q4 2025 at Anaptysbio, up from $15.1 million in the prior quarter.
  • Across five years, EBT topped out at $49.7 million in Q4 2025 and bottomed at -$46.7 million in Q2 2024.
  • Average EBT over 5 years is -$23.9 million, with a median of -$31.2 million recorded in 2021.
  • The sharpest move saw EBT crashed 6121.91% in 2022, then skyrocketed 328.06% in 2025.
  • Year by year, EBT stood at -$31.1 million in 2021, then rose by 28.8% to -$22.1 million in 2022, then crashed by 90.53% to -$42.2 million in 2023, then soared by 48.33% to -$21.8 million in 2024, then skyrocketed by 328.06% to $49.7 million in 2025.
  • Business Quant data shows EBT for ANAB at $49.7 million in Q4 2025, $15.1 million in Q3 2025, and -$38.6 million in Q2 2025.